{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T17:48:28Z","timestamp":1774028908413,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T00:00:00Z","timestamp":1495152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T00:00:00Z","timestamp":1495152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1038\/cgt.2017.17","type":"journal-article","created":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T11:28:57Z","timestamp":1495193337000},"page":"297-303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["An analysis of the polymorphisms of the GLUT1 gene in urothelial cell carcinomas of the bladder and its correlation with p53, Ki67 and GLUT1 expressions"],"prefix":"10.1038","volume":"24","author":[{"given":"C","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,19]]},"reference":[{"key":"BFcgt201717_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"BFcgt201717_CR2","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1517\/14728220903307509","volume":"13","author":"T Amann","year":"2009","unstructured":"Amann T, Hellerbrand C . GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets 2009; 13: 1411\u20131427.","journal-title":"Expert Opin Ther Targets"},{"key":"BFcgt201717_CR3","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3892\/ol.2011.394","volume":"2","author":"H Reis","year":"2011","unstructured":"Reis H, Tschirdewahn S, Szarvas T, Rubben H, Schmid KW, Grabellus F . Expression of GLUT1 is associated with increasing grade of malignancy in non-invasive and invasive urothelial carcinomas of the bladder. Oncol Lett 2011; 2: 1149\u20131153.","journal-title":"Oncol Lett"},{"key":"BFcgt201717_CR4","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1046\/j.1523-1755.2001.059003985.x","volume":"59","author":"AD Hodgkinson","year":"2001","unstructured":"Hodgkinson AD, Millward BA, Demaine AG . Polymorphisms of the glucose transporter (GLUT1) gene are associated with diabetic nephropathy. Kidney Int 2001; 59: 985\u2013989.","journal-title":"Kidney Int"},{"key":"BFcgt201717_CR5","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.2337\/diabetes.51.7.2264","volume":"51","author":"DP Ng","year":"2002","unstructured":"Ng DP, Canani L, Araki S, Smiles A, Moczulski D, Warram JH et al. Minor effect of GLUT1 polymorphisms on susceptibility to diabetic nephropathy in type 1 diabetes. Diabetes 2002; 51: 2264\u20132269.","journal-title":"Diabetes"},{"key":"BFcgt201717_CR6","doi-asserted-by":"publisher","first-page":"c182","DOI":"10.1159\/000118940","volume":"108","author":"M Rufino","year":"2008","unstructured":"Rufino M, Hernandez D, Barrios Y, Salido E . The GLUT-1 XbaI gene polymorphism is associated with vascular calcifications in nondiabetic uremic patients. Nephron Clin Pract 2008; 108: c182\u2013c187.","journal-title":"Nephron Clin Pract"},{"key":"BFcgt201717_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.cancergencyto.2005.07.004","volume":"163","author":"T Page","year":"2005","unstructured":"Page T, Hodgkinson AD, Ollerenshaw M, Hammonds JC, Demaine AG . Glucose transporter polymorphisms are associated with clear-cell renal carcinoma. Cancer Genet Cytogenet 2005; 163: 151\u2013155.","journal-title":"Cancer Genet Cytogenet"},{"key":"BFcgt201717_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3109\/09687688.2011.554447","volume":"28","author":"T Amann","year":"2011","unstructured":"Amann T, Kirovski G, Bosserhoff AK, Hellerbrand C . Analysis of a promoter polymorphism of the GLUT1 gene in patients with hepatocellular carcinoma. Mol Membr Biol 2011; 28: 182\u2013186.","journal-title":"Mol Membr Biol"},{"key":"BFcgt201717_CR9","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.2967\/jnumed.110.075721","volume":"51","author":"F Grabellus","year":"2010","unstructured":"Grabellus F, Sheu SY, Bachmann HS, Lehmann N, Otterbach F, Heusner TA et al. The XbaI G&gt;T polymorphism of the glucose transporter 1 gene modulates 18F-FDG uptake and tumor aggressiveness in breast cancer. J Nucl Med 2010; 51: 1191\u20131197.","journal-title":"J Nucl Med"},{"key":"BFcgt201717_CR10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nrc2715","volume":"9","author":"KH Vousden","year":"2009","unstructured":"Vousden KH, Ryan KM . p53 and metabolism. Nat Rev Cancer 2009; 9: 691\u2013700.","journal-title":"Nat Rev Cancer"},{"key":"BFcgt201717_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.tcb.2010.03.004","volume":"20","author":"Z Feng","year":"2010","unstructured":"Feng Z, Levine AJ . The regulation of energy metabolism and the IGF-1\/mTOR pathways by the p53 protein. Trends Cell Biol 2010; 20: 427\u2013434.","journal-title":"Trends Cell Biol"},{"key":"BFcgt201717_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cmet.2006.06.004","volume":"4","author":"JP Kruse","year":"2006","unstructured":"Kruse JP, Gu W . p53 aerobics: the major tumor suppressor fuels your workout. Cell Metab 2006; 4: 1\u20133.","journal-title":"Cell Metab"},{"key":"BFcgt201717_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.gde.2010.10.002","volume":"21","author":"Y Aylon","year":"2011","unstructured":"Aylon Y, Oren M . New plays in the p53 theater. Curr Opin Genet Dev 2011; 21: 86\u201392.","journal-title":"Curr Opin Genet Dev"},{"key":"BFcgt201717_CR14","doi-asserted-by":"crossref","unstructured":"Friedrich MG, Riethdorf S, Erbersdobler A, Tiemer C, Schwaibold H, Solter JK et al. Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder. European Urology 2001; 39: 159\u2013166.","DOI":"10.1159\/000052431"},{"issue":"7","key":"BFcgt201717_CR15","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1046\/j.1440-1827.2002.01371.x","volume":"52","author":"Nurcan Kilicli-Camur","year":"2002","unstructured":"Kilicli-Camur N, Kilicaslan I, Gulluoglu MG, Esen T, Uysal V. Impact of p53 and Ki-67 in predicting recurrence and progression of superficial (pTa and pT1) urothelial cell carcinomas of urinary bladder. Pathol Int 2002; 52: 463\u2013469.","journal-title":"Pathology International"},{"issue":"5","key":"BFcgt201717_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1078\/0344-0338-00424","volume":"199","author":"Bur\u00e7in Tuna","year":"2003","unstructured":"Tuna B, Yorukoglu K, Tuzel E, Guray M, Mungan U, Kirkali Z. Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer. Pathol Res Pract 2003; 199: 323\u2013328.","journal-title":"Pathology - Research and Practice"},{"key":"BFcgt201717_CR17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3390\/diagnostics3040372","volume":"3","author":"T Binderup","year":"2013","unstructured":"Binderup T, Knigge UP, Federspiel B, Sommer P, Hasselby JP, Loft A et al. Gene expression of glucose transporter 1 (GLUT1), hexokinase 1 and hexokinase 2 in gastroenteropancreatic neuroendocrine tumors: correlation with F-18-fluorodeoxyglucose positron emission tomography and cellular proliferation. Diagnostics 2013; 3: 372\u2013384.","journal-title":"Diagnostics"},{"issue":"5","key":"BFcgt201717_CR18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1159\/000020039","volume":"36","author":"Tapani Liukkonen","year":"1999","unstructured":"Liukkonen T, Rajala P, Raitanen M, Rintala E, Kaasinen E, Lipponen P. Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa\/T1) bladder cancer: a prospective comparative study. The Finnbladder Group. European Urol 1999; 36: 393\u2013400.","journal-title":"European Urology"},{"issue":"11","key":"BFcgt201717_CR19","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1002\/1097-0142(20000601)88:11<2598::AID-CNCR24>3.0.CO;2-N","volume":"88","author":"J. Wolter A. Oosterhuis","year":"2000","unstructured":"Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Smeets AW, Pauwels RP. MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance and comparison with other prognostic factors. Cancer 2000; 88: 2598\u20132605.","journal-title":"Cancer"},{"issue":"3","key":"BFcgt201717_CR20","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S0022-5347(05)67798-1","volume":"163","author":"TONY T. WU","year":"2000","unstructured":"Wu TT, Chen JH, Lee YH, Huang JK. The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 2000; 163: 758\u2013760.","journal-title":"Journal of Urology"},{"issue":"Suppl 2","key":"BFcgt201717_CR21","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1038\/modpathol.2009.1","volume":"22","author":"L Cheng","year":"2009","unstructured":"Cheng L, Montironi R, Davidson DD, Lopez-Beltran A . Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol 2009; 22 (Suppl 2): S70\u2013S95.","journal-title":"Mod Pathol"},{"key":"BFcgt201717_CR22","first-page":"138","volume":"8","author":"W Remmele","year":"1987","unstructured":"Remmele W, Stegner HE . Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987; 8: 138\u2013140.","journal-title":"Pathologe"},{"key":"BFcgt201717_CR23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/thy.2011.0401","volume":"22","author":"F Grabellus","year":"2012","unstructured":"Grabellus F, Worm K, Schmid KW, Sheu SY . The BRAF V600E mutation in papillary thyroid carcinoma is associated with glucose transporter 1 overexpression. Thyroid 2012; 22: 377\u2013382.","journal-title":"Thyroid"},{"key":"BFcgt201717_CR24","doi-asserted-by":"publisher","first-page":"8927","DOI":"10.1158\/0008-5472.CAN-06-1501","volume":"66","author":"JW Kim","year":"2006","unstructured":"Kim JW, Dang CV . Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006; 66: 8927\u20138930.","journal-title":"Cancer Res"},{"key":"BFcgt201717_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ceb.2007.02.003","volume":"19","author":"MC Brahimi-Horn","year":"2007","unstructured":"Brahimi-Horn MC, Chiche J, Pouyssegur J . Hypoxia signalling controls metabolicdemand. Curr Opin Cell Biol 2007; 19: 223\u2013229.","journal-title":"Curr Opin Cell Biol"},{"key":"BFcgt201717_CR26","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1046\/j.1523-1755.2001.059002631.x","volume":"59","author":"W Grzeszczak","year":"2001","unstructured":"Grzeszczak W, Moczulski DK, Zychma M, Zukowska-Szczechowska E, Trautsolt W, Szydlowska I . Role of GLUT1 gene in susceptibility to diabetic nephropathy in type 2 diabetes. Kidney Int 2001; 59: 631\u2013636.","journal-title":"Kidney Int"},{"key":"BFcgt201717_CR27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000052431","volume":"39","author":"MG Friedrich","year":"2001","unstructured":"Friedrich MG, Riethdorf S, Erbersdobler A, Tiemer C, Schwaibold H, Solter JK et al. Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder. Eur Urol 2001; 39: 159\u2013166.","journal-title":"Eur Urol"},{"key":"BFcgt201717_CR28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1046\/j.1440-1827.2002.01371.x","volume":"52","author":"N Kilicli-Camur","year":"2002","unstructured":"Kilicli-Camur N, Kilicaslan I, Gulluoglu MG, Esen T, Uysal V . Impact of p53 and Ki-67 in predicting recurrence and progression of superficial (pTa and pT1) urothelial cell carcinomas of urinary bladder. Pathol Int 2002; 52: 463\u2013469.","journal-title":"Pathol Int"},{"key":"BFcgt201717_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1078\/0344-0338-00424","volume":"199","author":"B Tuna","year":"2003","unstructured":"Tuna B, Yorukoglu K, Tuzel E, Guray M, Mungan U, Kirkali Z . Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer. Pathol Res Prac 2003; 199: 323\u2013328.","journal-title":"Pathol Res Prac"},{"key":"BFcgt201717_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000020295","volume":"38","author":"P Gontero","year":"2000","unstructured":"Gontero P, Casetta G, Zitella A, Ballario R, Pacchioni D, Magnani C et al. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol 2000; 38: 287\u2013296.","journal-title":"Eur Urol"},{"key":"BFcgt201717_CR31","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.eururo.2006.03.027","volume":"50","author":"AO Yurakh","year":"2006","unstructured":"Yurakh AO, Ramos D, Calabuig-Farinas S, Lopez-Guerrero JA, Rubio J, Solsona E et al. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol 2006; 50: 506\u2013515.","journal-title":"Eur Urol"},{"key":"BFcgt201717_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1159\/000020039","volume":"36","author":"T Liukkonen","year":"1999","unstructured":"Liukkonen T, Rajala P, Raitanen M, Rintala E, Kaasinen E, Lipponen P . Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa\/T1) bladder cancer: a prospective comparative study. The Finnbladder Group. Eur Urol 1999; 36: 393\u2013400.","journal-title":"Eur Urol"},{"key":"BFcgt201717_CR33","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1002\/1097-0142(20000601)88:11<2598::AID-CNCR24>3.0.CO;2-N","volume":"88","author":"JW Oosterhuis","year":"2000","unstructured":"Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Smeets AW, Pauwels RP . MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance and comparison with other prognostic factors. Cancer 2000; 88: 2598\u20132605.","journal-title":"Cancer"},{"key":"BFcgt201717_CR34","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S0022-5347(05)67798-1","volume":"163","author":"TT Wu","year":"2000","unstructured":"Wu TT, Chen JH, Lee YH, Huang JK . The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 2000; 163: 758\u2013760.","journal-title":"J Urol"},{"key":"BFcgt201717_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/jcp.2004.022939","volume":"59","author":"A Quintero","year":"2006","unstructured":"Quintero A, Alvarez-Kindelan J, Luque RJ, Gonzalez-Campora R, Requena MJ, Montironi R et al. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 2006; 59: 83\u201388.","journal-title":"J Clin Pathol"},{"key":"BFcgt201717_CR36","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.canlet.2005.11.006","volume":"242","author":"R Gonzalez-Campora","year":"2006","unstructured":"Gonzalez-Campora R, Davalos-Casanova G, Beato-Moreno A, Luque RJ, Alvarez-Kindelan J, Requena MJ et al. Apoptotic and proliferation indexes in primary superficial bladder tumors. Cancer Lett 2006; 242: 266\u2013272.","journal-title":"Cancer Lett"},{"key":"BFcgt201717_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1053\/ejso.2002.1371","volume":"29","author":"LL Santos","year":"2003","unstructured":"Santos LL, Amaro T, Pereira SA, Lameiras CR, Lopes P, Bento MJ et al. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder. Eur J Surg Oncol 2003; 29: 74\u201380.","journal-title":"Eur J Surg Oncol"},{"key":"BFcgt201717_CR38","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB . Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029\u20131033.","journal-title":"Science"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cgt201717.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201717","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/cgt.2017.17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201717.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T13:10:52Z","timestamp":1647954652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cgt201717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,19]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["BFcgt201717"],"URL":"https:\/\/doi.org\/10.1038\/cgt.2017.17","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,19]]},"assertion":[{"value":"20 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}